Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers.

Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M.

PLoS One. 2015 Dec 2;10(12):e0143178. doi: 10.1371/journal.pone.0143178. eCollection 2015.

2.

Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.

Dai W, Zeller C, Masrour N, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2013 Oct 15;19(20):5788-5797. doi: 10.1158/1078-0432.CCR-13-1217. Epub 2013 Aug 21.

3.

Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.

Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, Winham SJ, Vierkant RA, Rider DN, Block MS, Klotzle B, Konecny G, Winterhoff BJ, Hamidi H, Shridhar V, Fan JB, Visscher DW, Olson JE, Hartmann LC, Bibikova M, Chien J, Cunningham JM, Goode EL.

Hum Mol Genet. 2013 Aug 1;22(15):3038-47. doi: 10.1093/hmg/ddt160. Epub 2013 Apr 9.

4.

An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.

Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH.

Int J Cancer. 2009 Jan 15;124(2):387-93. doi: 10.1002/ijc.23957.

5.

An epigenetic signature in peripheral blood predicts active ovarian cancer.

Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ, Widschwendter M.

PLoS One. 2009 Dec 18;4(12):e8274. doi: 10.1371/journal.pone.0008274.

6.

Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients.

Flanagan JM, Wilhelm-Benartzi CS, Metcalf M, Kaye SB, Brown R.

Ann Oncol. 2013 Nov;24(11):2813-8. doi: 10.1093/annonc/mdt370. Epub 2013 Oct 10.

7.

Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.

Huang RL, Gu F, Kirma NB, Ruan J, Chen CL, Wang HC, Liao YP, Chang CC, Yu MH, Pilrose JM, Thompson IM, Huang HC, Huang TH, Lai HC, Nephew KP.

Epigenetics. 2013 Jun;8(6):624-34. doi: 10.4161/epi.24816. Epub 2013 May 10.

8.

Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.

Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, Roman LD, Berchuck A, Pearce CL, Laird PW.

PLoS One. 2011;6(12):e28141. doi: 10.1371/journal.pone.0028141. Epub 2011 Dec 7.

9.

RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.

Häfner N, Steinbach D, Jansen L, Diebolder H, Dürst M, Runnebaum IB.

Int J Cancer. 2016 Jan 1;138(1):217-28. doi: 10.1002/ijc.29690. Epub 2015 Jul 28.

10.

Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma.

Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL.

PLoS One. 2013;8(2):e55761. doi: 10.1371/journal.pone.0055761. Epub 2013 Feb 20.

11.

Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer.

Koestler DC, Chalise P, Cicek MS, Cunningham JM, Armasu S, Larson MC, Chien J, Block M, Kalli KR, Sellers TA, Fridley BL, Goode EL.

BMC Med Genomics. 2014 Jan 30;7:8. doi: 10.1186/1755-8794-7-8.

12.

Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.

Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, Stronach E, Millan DW, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. Epub 2011 Apr 1.

13.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

14.

Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.

Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, Brown R, Huang TH.

Clin Cancer Res. 2002 Jul;8(7):2246-52.

15.

Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines.

Sánchez-Vega F, Gotea V, Petrykowska HM, Margolin G, Krivak TC, DeLoia JA, Bell DW, Elnitski L.

Epigenetics. 2013 Dec;8(12):1355-72. doi: 10.4161/epi.26701. Epub 2013 Oct 22.

16.

The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer.

Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, Kitchener HC, Teschendorff AE, Widschwendter M.

PLoS Genet. 2012 Feb;8(2):e1002517. doi: 10.1371/journal.pgen.1002517. Epub 2012 Feb 9. Erratum in: PLoS Genet. 2012 Mar;8(3). doi: 10.1371/annotation/35f168f3-c509-4b4f-b245-f6682325838e.

17.

Epigenetics in ovarian cancer.

Seeber LM, van Diest PJ.

Methods Mol Biol. 2012;863:253-69. doi: 10.1007/978-1-61779-612-8_15. Review.

PMID:
22359298
18.

5'-Hydroxymethylcytosine Precedes Loss of CpG Methylation in Enhancers and Genes Undergoing Activation in Cardiomyocyte Maturation.

Kranzhöfer DK, Gilsbach R, Grüning BA, Backofen R, Nührenberg TG, Hein L.

PLoS One. 2016 Nov 16;11(11):e0166575. doi: 10.1371/journal.pone.0166575. eCollection 2016.

19.

Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.

Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, Zwarthoff EC.

Eur Urol. 2012 Jun;61(6):1245-56. doi: 10.1016/j.eururo.2012.01.011. Epub 2012 Jan 18.

PMID:
22284968

Supplemental Content

Support Center